Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
Mariko Harada‐Shiba, Michael H. Davdison, Marc Ditmarsch, et al.
Journal of Atherosclerosis and Thrombosis (2024)
Open Access | Times Cited: 9

Showing 9 citing articles:

Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, et al.
American Heart Journal (2024) Vol. 274, pp. 32-45
Open Access | Times Cited: 15
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
N. Lan, Gerald F. Watts
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Open Access
A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
Jing Zhang, Guoying Cao, Yong Huo, et al.
The Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 2
Obicetrapib: There is still Life in the CETP Inhibitor!
Masatsune Ogura
Journal of Atherosclerosis and Thrombosis (2024)
Open Access | Times Cited: 1
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials
Stephen J. Nicholls, Adam J. Nelson, John J.P. Kastelein, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 1
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity
Michael H. Davidson, Andrew Hsieh, John J.P. Kastelein
Current Opinion in Lipidology (2024) Vol. 35, Iss. 6, pp. 303-309
Open Access
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis.
Walter Masson, Leandro Barbagelata, Martín Lobo, et al.
Journal of clinical lipidology (2024)
Closed Access
New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease
N. Lan, Gerald F. Watts
Current Opinion in Endocrinology Diabetes and Obesity (2024)
Closed Access
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Stephen J. Nicholls, Sean Tan, Julie Butters, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access
Page 1

Scroll to top